We have previously shown that cytochrome P450 1A1 (CYP1A1) was highly induced for a long period of time in a patient who had been poisoned by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a compound known to activate the aryl hydrocarbon receptor (AhR). During that period of time, no sebaceous glands could be observed in the skin of this patient. In this study, starting from observations in the patient exposed to TCDD, we analyzed the seboatrophy induced by dioxins in mice. We observed a very different pattern of AhR and CYP1A1 immunostaining in skin biopsies of the patient. When applying TCDD and beta-naphthoflavone, another AhR agonist, on the ears of C57BL/6J mice, we reproduced (1) an atrophy of sebaceous glands, (2) a strong induction of CYP1A1 within the glands, and (3) a dramatic repression of the genes encoding the sebogenic enzymes AWAT1, ELOVL3, and SCD1. These effects were reversible. Leucine-rich repeats and immunoglobulinlike domains protein 1 (LRIG1) expressing progenitor cells, found in the vicinity of sebaceous glands, were shown to be the initial skin cellular targets of AhR agonists. These cells retained the DNA label BrdU and colocalized with the CYP1A1 protein for at least 30 days. A downregulation of LRIG1 by siRNA in cultured sebocytes significantly decreased the CYP1A1 response to TCDD, indicating that LRIG1 contributes to a higher susceptibility of AhR agonists. In conclusion, these observations provide for the first time a strong experimental support to the concept that dioxin-induced skin pathology may be driven by a molecular switch in progenitor cells involved in the physiological turnover of sebaceous glands.
(XREs) found on the promoter regions of these genes (Sorg, 2014) . The gene that is the most highly activated encodes the cytochrome P450 1A1 (CYP1A1) enzyme.
Sebaceous glands are skin appendages constituted by sebocytes, a kind of specialized cells that produce sebum, a lipidrich medium forming a protective film at the surface of the skin; fully differentiated sebocytes are filled from sebum and release their lipid content by holocrine secretion (Schneider and Paus, 2010; Thody and Shuster, 1989) . The proteins MTS24, keratin 15, and leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG1) are known biomarkers of skin progenitor cells. MTS24 is a biomarker of progenitor cells localized between sebaceous glands and the hair follicle bulge (Nijhof et al., 2006) , keratin k15 is a marker of skin progenitor cells found in the bulge of hair follicles (Bose et al., 2013) , whereas LRIG1 is a transmembrane protein expressed by epidermal progenitor cells, which maintains the upper pilosebaceous unit containing the infundibulum and sebaceous glands (Page et al., 2013) .
When me made our first immunohistochemical stainings of AhR and CYP1A1 from skin biopsies of our patient, we were surprised to find that the pattern of AhR expression was quite different from that of CYP1A1, the gene of which is induced following AhR signaling (Saurat et al., 2012) : AhR was mostly expressed in the epidermis, whereas CYP1A1 was localized on the walls of the new hamartoma structures that replaced sebaceous glands. We hypothesized that TCDD might target a particular subpopulation of skin progenitor cells that normally migrate to the pilosebaceous follicle and differentiate to sebocytes to maintain the turnover of sebaceous glands. Following TCDD exposure, these progenitor cells would no longer differentiate into sebocytes but produce the so-called MADISH. The aim of this study was to reproduce the atrophy of sebaceous glands in mice and to analyze the phenotype of the cells expressing preferentially CYP1A1 following exposure to AhR agonists.
MATERIALS AND METHODS
Clinical specimens. Skin sampling was performed under general anesthesia during therapeutic procedures.
Chemicals. TCDD (Cambridge Isotope Laboratories) was purchased from ReseaChem (Burgdorf, Switzerland), the sebocyte growth medium from Zenbio Inc (Research Triangle Park, North Carolina), FBS (Hyclone) from Fisher Scientific (Reinach, Switzerland), cholera toxin from Gentaur (Kampenhout, Belgium), BNF from Enzo Life sciences, Lausen, Switzerland, and the other chemicals from Sigma Aldrich (Buchs, Switzerland).
Animals. Adult male C57BL/6J mice 4-6 weeks old were purchased from Charles River (Lyon, France). For topical applications, 100 ml of the solutions were applied on each ear once a day for the indicated number of days. At the end of the experiment, the mice were sacrificed by CO 2 inhalation and the skin was harvested, fixed in formaldehyde (4%) or frozen and stored at À80
C. Intraperitoneal injections of TCDD (90 mg/kg) and bnaphthoflavone (BNF) (20 mg/kg) were performed in 100 ml sunflower oil. For cell lineage tracing, 2-week-old mice were injected intraperitoneally with 100 ml 5-bromo-2 0 -deoxyuridine (BrdU) 12.5 mg/ml in Dulbecco's modified phosphate buffer saline every 12 h for a total of 4 injections. All experimental procedures on mice were performed according to the Swiss legislation and with the authorization of the Swiss Federal Veterinary Administration.
Cell culture and siRNA. Primary sebocytes from human origin were purchased from Zenbio Inc and cultured in the Sebocyte Growth Medium from Zenbio according to the manufacturer's instructions. siRNA interference experiments were performed by transfecting the sebocytes with LipofectamineRNAiMAX and Opti-MEM from Invitrogen (Fisher Scientific) according to the manufacturer's instructions. Silencer Select predesigned siRNAs for LRIG1 (s24973) and a negative control (4390843) were purchased from Ambion (Fisher Scientific). The medium was changed 24 h after the transfection; 48 h after the transfection, TCDD (1 nM) or ethanol was applied, then 24 h later, RNA extraction or 7-ethoxyresorufin-O-deethylase (EROD) assay was performed.
Immunohistochemistry. AhR and CYP1A1 immunostaining were performed in fixed sections as previously described (Lebeau et al., 2005) ; rabbit polyclonal anti-Ahr antibody (Abcam, Cambridge, UK), mouse anti-human CYP1A1 (Santa Cruz Biotechnology, LabForce, Muttenz, Switzerland), and rabbit antirat Cyp1a1 antibodies (Chemicon, VWR, Dietikon, Switzerland) were used. Double fluorescence immunostaining was performed to detect a colocalization with Cyp1a1 and other cell Figure 1 . Tissue 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and cytochrome P450 1A1 (CYP1A1) expression in Victor Yushchenko. A, CYP1A1 expression, expressed as fold change versus the mean of 4 matched controls (sex, age, and area of origin) in skin biopsies taken at various time points after TCDD exposure; TCDD concentrations in serum lipids from blood samples taken at the same time points were published previously (Sorg et al., 2009) . B, TCDD concentrations in whole serum and in MADISH-like lesions from skin biopsies taken at various time points after TCDD exposure; the data come from a figure shown in our previous publication (Sorg et al., 2009 following CYP1A1 and second antibody incubation, skin sections were postfixed in 4% formaldehyde, then rat anti-BrdU (AbD Serotec, Bio-Rad, Puchheim, Germany) was incubated with Alexa Fluor 488 conjugated second antibody. Images were obtained using a Zeiss LSM 700 confocal microscope.
Transcriptomic analysis. The expression of the gene encoding CYP1A1 in human (Victor Yushchenko) was performed using whole genome microarray transcriptomic analysis as previously described (Saurat et al., 2012) . The levels of expression of various genes in mice were analyzed by real-time quantitative PCR at the Institute of Genetics and Genomics of Geneva (see Supplementary Table 1 for primer sequences). cDNA was synthesized from 0.5 mg of total RNA using a mix of random hexamers-oligo d(T) primers and PrimerScript reverse transcriptase enzyme (Takara Bio Inc Kit) following suppliers instructions. Sybr green assays were designed using the program Primer Express v 2.0 (Applied Biosystems) with default parameters. Amplicons sequences were aligned against the mouse genome by BLAST to ensure that they were specific for the gene being tested (see Supplementary Figure  1 for amplicon efficiency).
Oligonucleotides were obtained from Invitrogen. PCR reactions (10 ml volume) contained diluted cDNA (1:40), 2 Â PowerUP SYBR Green Master Mix (Applied Biosystems), 300 nM of forward and reverse primers. PCR were performed on a SDS 7900 HT instrument (Applied Biosystems) with the following parameters: 50 C for 2 min, 95 C for 10 min, and 45 cycles of 95 C 15 s-60 C 1 min. Each reaction was performed in 3 replicates on 384-well plate. Raw Ct values obtained with SDS 2.2 (Applied Biosystems) were imported in Excel and normalization factor and fold changes were calculated using the GeNorm method.
CYP1A1 activity. The activity of CYP1A1 was analyzed in cultured human sebocytes using the EROD assay as previously described (Barouti et al., 2015) . Briefly, a nonfluorescent CYP1A1 substrate, 7-ethoxyresorufin, is applied on cultured hepatocytes, then the fluorescence of the product, resorufin, is analyzed using a plate reader (Schiwy et al., 2015) .
Statistical analyses. The Student's t-test was performed to compare a treatment with its vehicle for the PCR data of the sebogenic enzymes ELOVL3, AWAT1, and SCD1. fold change value was < 1, the repression factor, corresponding to (À1/fold change) was reported in the graph. Note that the scale of Y-axis is different for C and D.
Statistical analyses: at the beginning of the recovery (0 week), the P values for the 3 enzymes were < .01 with both TCDD and BNF, whereas at the end of the recovery (8 weeks), the P values were higher than.05 for all 3 enzymes with BNF. With TCDD at 8 weeks, the P value was < .01, > .05, and < .05 for ELOVL3, AWAT1, and SCD1, respectively.
RESULTS

Evolution of Dioxin Concentrations and Expression of CYP1A1, AhR, and Lrig1 in Victor Yushchenko
Dioxins, and in particular TCDD, have a very long biological half-life. In Victor Yushchenko, the blood TCDD concentration decreased from 107 ng/g lw (lipid weight) to 20 ng/g lw over a 3.5 year period (mean value in the general population for the TCDD equivalent concentration (TEQ), which accounts for all dioxin-like compounds: 5-25 pg/g lw); during the same period of time CYP1A1 expression in the skin decreased from 175-to 49-fold the control level ( Figure 1A ). The TCDD concentrations in lesional skin followed a delayed kinetics compared with that of serum, reaching a maximum between 10 and 20 months after TCDD exposure ( Figure 1B ), corresponding to the maximal intensity of the cutaneous syndrome (Saurat et al., 2012) . During this period, the skin concentrated TCDD from the blood, which explains the delayed kinetics. The very slow decrease of TCDD body burden and of TCDD-induced gene expression modulation, as exemplified by CYP1A1, explains the slow recovery of the skin condition induced by TCDD. Eleven months after TCDD exposure, AhR was expressed in the whole epidermis (Figure 2A ), whereas CYP1A1 expression was surprisingly sparing the epidermis and localized in the epithelial wall of the so-called MADISH lesions that had replaced sebaceous glands and in endothelial cells ( Figure 2B ); in particular, CYP1A1 was still highly expressed in the mentioned structures, whereas no sebaceous glands could be observed in many skin biopsies taken during this period ( Figure 2B , Saurat et al., 2012) . At the same time, 2 markers of pluripotent cells associated to the pilosebaceous unit, keratin 15 and LRIG1, were observed in a pattern very similar to that of CYP1A1 (Figs. 2C and 2D) . This led us to suspect Lrig1 expressing cells to be the first skin target of TCDD, at the origin of the seboatrophy observed in the weeks following TCDD exposure.
Sebaceous Gland Recovery and Gene Expression Analysis Following Topical AhR Agonists in Mice
To analyze the involvement of AhR signaling pathway in the atrophy of sebaceous glands induced by TCDD, we treated mice with either TCDD or BNF by topical application on the ears for 5 weeks, then we analyzed the recovery of sebaceous glands in parallel to the expression of genes involved in sebogenesis. BNF, an AhR agonist structurally unrelated to TCDD, is commonly used to analyze the metabolism of aromatic hydrocarbons by the CYP1A1 (Gravato et al., 2006) . In TCDD-treated mice, the density of sebaceous glands reached a minimum of 27% of control mice 2-4 weeks after the end of treatment, and the recovery was only 51% 8 weeks after the end of treatment ( Figure 3A) , whereas in BNF-treated mice, the minimum density was observed at the end of treatment (42% of control mice), and the recovery was faster and almost complete 8 weeks later ( Figure 3B ). At the end of treatment, TCDD and BNF induced 100-and 63-fold increase of Cyp1a1 expression, respectively, then Cyp1a1 expression returned to basal level faster with BNF compared with TCDD (Figs. 3A and 3B ). The expression of genes encoding Elovl3 (elongation of very long chain fatty acids 3), Awat1 (acyl-coA wax alcohol acyltransferase 1), and Scd1 (stearoyl-coA desaturase 1), 3 enzymes involved in sebogenesis (Guillou et al., 2010; Turkish et al., 2005) , was significantly reduced at the end of treatment, to a higher extent with TCDD, then returned progressively to basal level, faster for Awat1 than for the other 2 (Figs. 3C and 3D) .
At the end of TCDD and BNF treatment, the morphology of the remaining sebaceous glands was dramatically altered. Almost no normal sebocyte could be seen in the remaining sebaceous gland structures; 8 weeks after the end of treatment, the appearance of sebaceous glands completely recovered in BNF-treated mice, whereas in the case of TCDD the morphology was still affected (Figs. 4A-F) .
CYP1A1 Induction in Sebaceous Glands After Topical or Systemic
Exposure to AhR Agonists in Mice TCDD and BNF were applied topically for 24 h on mouse ears to determine the first skin targets of AhR agonists using CYP1A1 immunolabeling. Twenty-four hours following one application, only sebaceous glands expressed Cyp1a1 in both TCDD-and BNF-treated mice (Figs. 5A-C) , indicating that sebaceous glands are the most sensitive skin structures to the activation of AhR signaling pathway. Because sebaceous glands are quite accessible following topical treatment, to confirm their sensitivity to AhR agonists we treated mice by ip injection with TCDD or BNF to see if a systemic exposure to AhR agonists could target sebaceous glands too. As shown in Figs. 5D-F, TCDD and BNF targeted only sebaceous glands 24 h following ip injection.
Do AhR Agonists Target Skin Progenitor Cells in Mice?
A possible explanation of the cutaneous manifestations of dioxin intoxication is an induction of a "molecular switch" to progenitor cells involved in sebogenesis. We have seen that CYP1A1 is a sensitive biomarker of cells targeted by dioxin and other AhR agonists. To characterize the progenitor cells that respond to dioxin, we performed double immunostaining with Cyp1a1 and various progenitor cell biomarkers a short period of time following topical application with TCDD on mouse ears. As shown in Figure 6 , Mts24, a biomarker of progenitor cells localized between sebaceous glands and the hair follicle bulge (Nijhof et al., 2006) , did not colocalize with Cyp1a1 target cells 6 or 12 h after topical TCDD. On the other hand, Lrig1, a transmembrane protein found on the hair follicle junctional zone Figure 5 . CYP1A1 expression in mouse skin following topical or systemic exposure to AhR agonists. C57BL/6J mice (3 per treatment condition) were treated either topically on the ears with acetone (vehicle) (A), TCDD 2 mg/ml in acetone (6 mM) (B) or BNF 10 mg/ml in acetone (37 mM) (C), or by ip injections with 90 mg/kg TCDD (E), 20 mg/kg BNF (F) or vehicle (170 ml sunflower oil) (D) and were sacrificed 12 h (vehicle, TCDD) or 24 h (BNF) later; skin samples were processed for H/E staining and CYP1A1 immunolabeling (brown color). Arrows show unlabeled sebaceous glands in control mice (A and D) and CYP1A1 expression in sebaceous glands of mice treated with AhR agonists (B, C, E, and F). adjacent to the sebaceous glands and infundibulum (Jensen et al., 2009) , colocalized with Cyp1a1 target following an early activation by TCDD on mouse ears (Figure 7) .
We then tried to reproduce the colocalization of Cyp1a1 and progenitor cell biomarkers after a systemic exposure to TCDD. The Cyp1a1 expression started to be visible 12 h after ip injection of TCDD (Figs. 8 and 9 ). As for topical application, there was no colocalization between Cyp1a1 and Mts24 (Figure 8 ), whereas Lrig1 colocalized with Cyp1a1 ( Figure 9 ).
CYP1A1 Expression in DNA Label-Retaining Cells in Mice
To confirm the progenitor property of early CYP1A1 expressing cells following AhR agonist exposure, we performed a cell lineage tracing using the DNA label BrdU. Thirty days after the last BrdU injection and 24 h after AhR activation, some cells located in the infundibulum part of the pilosebaceous unit retained the BrdU label, among which 28% and 57% also expressed Cyp1a1 after TCDD and BNF exposure, respectively ( Figure 10) ; this confirms the progenitor property of the first cells targeted by AhR agonists.
Effect of LRIG1 on CYP1A1 Activation by TCDD in Cultured Sebocytes
Because the first cells targeted by TCDD also express LRIG1, we wondered whether LRIG1 participated to the activation of CYP1A1. To test this hypothesis, we performed a downregulation of LRIG1 in cultured sebocytes using siRNA. As shown in Figure 6 . Expression of CYP1A1 and MTS24 in mouse skin following topical application of TCDD. C57BL/6J mice (3 per treatment condition) received one application of TCDD 2 mg/ml in acetone (6 mM) or acetone alone (vehicle). Mice were sacrificed 6 or 12 h later as indicated, then skin samples were processed for MTS24 expression (green) and CYP1A1 (red) by immunofluorescence; nuclei were visualized using 4 0 ,6 0 -diamidino-2-phenylindole (DAPI) (blue). As shown in the third line of pictures, there is no colocalization of CYP1A1 and MTS24 (no yellow light from red and green superimposition). Figure 11 , both the expression of CYP1A1 gene and the enzymatic activity of CYP1A1 were significantly reduced following TCDD exposure in Lrig1 downregulated cultured sebocytes.
DISCUSSION
In this study, we first analyzed in skin biopsies of V. Yushchenko the expression of AhR and CYP1A1 genes at some time points following TCDD poisoning, to approach the part of the skin that was preferentially responsive to TCDD. Surprisingly, CYP1A1, a gene induced following AhR activation, presented a very different pattern of expression compared with AhR. The latter was highly and uniformly expressed in the whole epidermis, whereas CYP1A1 was almost absent from the epidermis and highly expressed in the epidermoid wall of the newly formed dermal hamartoma. This suggests that several factors may contribute to a variable susceptibility to AhR agonists of skin cells, depending on their differentiation programme. This segregation is likely to drive the type of the skin pathology induced by TCDD. Following a single acute exposure by TCDD, the plasma concentration of this AhR agonist decreased very slowly and was still highly induced 40 months after TCDD exposure (Sorg et al., 2009) . The activation of CYP1A1 followed the same kinetics, which confirms the tight Figure 7 . Expression of CYP1A1 and Lrig1 in mouse skin following topical application of TCDD. C57BL/6J mice (3 per treatment condition) received one application of TCDD 2 mg/ml in acetone (6 mM) or acetone (vehicle). Mice were sacrificed 6 or 12 h later as indicated, then skin samples were processed for Lrig1 expression (green) and CYP1A1 (red) by immunofluorescence; nuclei were visualized using DAPI (blue). The colocalization of CYP1A1 and Lrig1 can be seen in the third line of pictures in yellow (superimposition of green and red light).
relationships between AhR activation and CYP1A1 expression in humans, with little tendency to downregulation. Indeed, it was surprising that the natural downregulator of AhR activation, the AhR repressor (AhRR)-a gene induced following AhR activation (Saurat et al., 2012) -did not antagonize the sustained CYP1A1 activation. This could be explained by the long-term persistence of TCDD in body fat, from which a continuous flux reaches the skin. It is also possible that AhRR is induced only transiently, even during a long-term presence of TCDD, unlike CYP1A1. We couldn't verify this hypothesis because our patient came to Geneva only 4 months after the supposed exposure of TCDD, so we had no skin biopsies before that time.
We have previously shown that during this long period of time no sebaceous glands could be seen in the numerous skin biopsies taken in this patient (Saurat et al., 2012) . We reproduced such an atrophy of sebaceous glands in C57BL/6J mice following topical application of the AhR agonists TCDD and BNF during a 5 week period of time. The first question we addressed was the reversibility of this effect. We observed that several weeks after the end of treatment leading to a significant decrease of sebaceous gland density and an alteration of their morphology, the density and the morphology of sebaceous glands, as well as CYP1A1 expression, tended to return to the control condition, indicating that the seboatrophy is reversible, at least in mice. 90 mg/kg TCDD in sunflower oil and were sacrificed 6, 12, or 24 h later as indicated; skin samples were processed for MTS24 expression (green) and CYP1A1 (red) by immunofluorescence; nuclei were visualized using DAPI (blue). As shown in the third line of pictures, there is no colocalization of CYP1A1 and MTS24 (no yellow light from red and green superimposition).
The kinetics of reversibility was however slower for TCDD, which is a much stronger AhR agonist (EC 50 ffi 0.1 nM) than BNF (EC 50 ffi 1 mM), as observed in our EROD assay (not shown). In V. Yushchenko, we also observed a dramatic decrease of several genes encoding enzymes involved in the production of sebum lipids such as ELOVL3, AWAT1, and SCD1 (Saurat et al., 2012) . In our study, in mice these 3 genes were significantly decreased at the end of the period of AhR activation, and returned to control values in 8 weeks. All these observations made us confident to use this mouse model to decipher the mechanism of seboatrophy following AhR activation. The first cells where CYP1A1 expression is increased are sebocytes. Because sebaceous glands are localized close to the site of application of the compounds, we wondered whether this selectivity of CYP1A1 was really specific. To confirm that sebaceous glands are the first targets of AhR activation we injected TCDD and BNF intraperitoneally and observed the cells expressing CYP1A1 24 h later. The doses were chosen to be below the DL 50 , but high enough to reach the skin quickly, before the development of a whole response of the organism that could alter the first distribution of the CYP1A1. Again the only cells inducing CYP1A1 a short period of time after AhR activation were sebocytes, which confirms that sebaceous glands are the first targets of AhR agonists. During the natural turnover of sebaceous glands, sebocytes are progressively filled with sebum during their maturation, and once fully differentiated they degenerate and secrete the sebum by a holocrine process (Thody and Shuster, 1989) . To maintain the normal turnover of the glands, a signal should be given to progenitor cells localized in the vicinity of the pilosebaceous units to stimulate them to migrate to the periphery of sebaceous glands and to differentiate to sebocytes. To identify the progenitor cells targeted by AhR agonists, we looked for skin progenitor cell markers that might colocalize with CYP1A1. The cell surface protein MTS24, which is expressed by follicular keratinocytes with progenitor cell characteristics (Nijhof et al., 2006) , did not colocalize with CYP1A1, whereas the multipotent Figure 10 . Cell lineage tracing: CYP1A1 expression in cells retaining DNA labeling following AhR agonists. C57BL/6J mice (3 per treatment condition) were injected intraperitoneally with BrdU 12.5 mg/ml in 200 ml Dulbecco's modified phosphate buffer saline (total 2.5 mg or 6 mmol) at days 1 and 2 (7 AM and 7 PM); TCDD 2 mg/ml in acetone (6 mM) (A) or BNF 10 mg/ml in acetone (37 mM) (B) were applied on mouse ears at day 29, then mice were sacrificed 24 h later and skin samples were processed for BrdU (green) and CYP1A1 expression (red) by immunofluorescence; nuclei were visualized using DAPI (blue). The colocalization of CYP1A1 and BrdU can be seen on the third picture (right) in turquoise (superimposition of green, blue, and red light).
epidermal progenitor cell marker LRIG1, found in the junctional zone adjacent to the sebaceous glands (Jensen et al., 2009; Page et al., 2013) , colocalized with CYP1A1. Using the BrdU technique of cell lineage tracing, we confirmed that Lrig1 expressing cells retained the DNA label, and CYP1A1 still colocalized with these cells 30 days after the last BrdU injection. This long-term colocalization of Lrig1 and CYP1A1 led us to analyze a putative interaction between LRIG1 and TCDD-induced CYP1A1 activation. In cultured sebocytes, using siRNA to downregulate LRIG1 gene, both the expression of CYP1A1 gene and the enzymatic activity of the CYP1A1 protein were significantly decreased following TCDD. LRIG1 is known to antagonize the activity of epidermal growth factor (EGF) by enhancing the degradation of its receptor (EGFR) by ubiquitylation (Gur et al., 2004; Wong et al., 2012) . On the other hand, Sutter et al. (2009) demonstrated that EGFR activation negatively modulated AhR signaling in human epidermal keratinocytes. This explains our result on human epidermal keratinocytes: when downregulating LRIG1 gene using siRNA, EGF antagonism is repressed, and thus AhR signaling is decreased by EGF pathway, leading to a decrease of CYP1A1 activation by TCDD.
AhR, once believed to be mostly the mediator of the toxicity of dioxin-like compounds, is now also investigated to understand all its biological functions. A great diversity of compounds structurally unrelated to the dioxin-like family and found in soybean products or vegetables such as brassicaceae have been shown to activate the AhR signaling pathway without inducing a chloracne-like syndrome or any other skin condition in people who consume these dietary compounds (Amakura et al., 2011; Connor et al., 2008; Denison and Nagy, 2003; Stejskalova et al., 2011) . This indicates that the toxicity of dioxin-like compounds, in particular chloracne (development of MADISH) cannot be explained only by the activation of AhR signaling pathway. The diversity of biological actions elicited by dioxins may be explained by noncanonical AhR signaling pathways (Guyot et al., 2013; Puga et al., 2009) . For instance, XREs have been shown to contribute to the functional structure of the genome, the circadian rhythm and the immune system (Esser, 2012) . In particular, AhR signaling may be involved in cell reprogramming via the expression of the microRNA miR-302 (Hu et al., 2013) . Homeostasis of progenitor cells requires a balance between proliferation and differentiation, and this regulation depends on the cell type and the microenvironment (Bock, 2017) . AhR functions in cooperation with c-Myc and its inhibitor Blimp1, which regulate the homeostasis of stem/progenitor cells in a noncanonical way. Hence, a sustained activation of AhR, such as observed after an acute exposure to TCDD, leads to a dysregulation of sebaceous gland homeostasis and finally to chloracne (Bock, 2016; Ikuta et al., 2010; Saurat et al., 2012) .
In conclusion, we studied in mice the seboatrophy induced by AhR agonists such as TCDD and BNF. The first cells targeted by these compounds are multipotent progenitor cells expressing LRIG1, which are believed to be involved in the natural turnover of sebaceous glands. We observed a similar atrophy of sebaceous glands in transgenic mice where Lrig1 expressing cells were selectively suppressed postnatally (manuscript in preparation). A signal should come from the skin surface during holocrine secretion of sebum by differentiated sebocytes to induce these progenitor cells to migrate to sebaceous glands and differentiate to new sebocytes. This signaling seems to be disturbed by TCDD and related compounds, and the targeted progenitor cells no longer differentiate to sebocytes, but produce the so-called MADISH, the hallmark lesions of the cutaneous syndrome induced by dioxin-like compounds. To understand the relationship between seboatrophy and MADISH production, new models should be developed, because mice don't appear to produce MADISH after TCDD treatment, in spite of a sebotrophy, as shown in this study. The biological half-life of TCDD is much shorter in rodents (11 days for C57BL/6J mice (Gasiewicz et al., 1983) ) than in humans (1-8 years, depending of the age and the body burden (Kerger et al., 2006) ), and the time required to induce MADISH in rodents after TCDD treatment might be longer than the lifespan of these animals, due to the general toxicity of TCDD. A less toxic chloracnegen should be used to understand the mechanism linking seboatrophy to chloracne in rodents. Indeed, the development of MADISH-like lesions in mice have been observed once after a 2-year gavage of the chloracnegen 3,3 0 ,4,4 0 -tetrachlorazobenzene (Ramot et al., 2009 ).
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